MDGL Stock Hits Fresh 52-Week Low On Near-Term Profitability Concerns, But Citi Sees Over 75% Upside

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, up 50% YoY, driven by demand for Rezdiffra. The company had 55,850 active Rezdiffra patients, nearly double the previous year. Madrigal expects the U.S. F2/F3 MASH market to grow 30% by year-end, with Rezdiffra penetrating about 1% of the total opportunity.

Madrigal Pharmaceuticals reported its first profitable quarter with $55.4M net income and $1B year-to-date sales. Rezdiffra's annual sales exceed $1.7B. The company revised its addressable patient population upward by 45% and expects continued growth in the MASH and F4c markets. Management anticipates initiating new clinical trials in 2027 and projects a gross-to-net range of mid-to-high 30% for 2027.

Madrigal Pharmaceuticals (MDGL) reported Q3 net income of $55.4M, up from a $114.2M loss last year. The company expects sequential growth in Q4 and is expanding its commercial outreach. Madrigal is advancing its F4c MASH development program, with trial results expected in late 2027. The company plans to initiate three Phase II combination trials in 2027 and presented real-world data at a liver disease meeting.

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 profit of $55.4M, reversing a $114.2M loss from 2025, driven by 50% revenue growth to $431.3M. Rezdiffra sales surpassed $1B year-to-date, achieving blockbuster status. The company plans new trials for expanded use in cirrhosis patients. CEO Bill Sibold cited strong demand and market growth.

Madrigal Pharmaceuticals (MDGL) reported a Q3 profit of $55.44M, reversing a year-earlier loss, driven by a 50% sales increase of Rezdiffra to $431.30M. R&D expenses declined, while SG&A and cost of sales rose. Over 55,850 patients are now using Rezdiffra, and the company plans a Phase 3 trial for MASH cirrhosis in 2027. MDGL stock is up 9.89%.

Madrigal Pharmaceuticals reported Q3 2026 revenue of $431.27M, up 50.1% YoY, and net income of $55.44M, reversing a prior-year loss. EPS was $1.83 vs. a loss of $4.01. Rezdiffra revenue grew 74% over nine months, with U.S. demand driving quarterly gains. The company expanded its field force and launched Rezdiffra in Germany.